Zacks Investment Research cut shares of Achaogen, Inc. (NASDAQ:AKAO) from a buy rating to a hold rating in a report issued on Tuesday.

According to Zacks, “Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. “

Several other research analysts have also commented on the stock. Leerink Swann assumed coverage on shares of Achaogen in a research note on Wednesday, January 4th. They set an outperform rating and a $21.00 price objective for the company. Wedbush reissued an outperform rating and set a $19.00 target price (up from $10.00) on shares of Achaogen in a research note on Thursday, December 15th. Cowen and Company reissued a buy rating on shares of Achaogen in a research note on Tuesday, December 13th. Needham & Company LLC raised shares of Achaogen from a hold rating to a buy rating and set a $19.00 target price for the company in a research note on Monday, December 12th. Finally, Aegis started coverage on shares of Achaogen in a research note on Wednesday, November 2nd. They set a buy rating and a $10.00 target price for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $16.00.

Achaogen (NASDAQ:AKAO) opened at 15.90 on Tuesday. The company’s market capitalization is $436.47 million. The company has a 50 day moving average of $9.82 and a 200 day moving average of $5.59. Achaogen has a 52 week low of $2.59 and a 52 week high of $16.60.

Achaogen (NASDAQ:AKAO) last posted its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.20. The company earned $16.05 million during the quarter, compared to analyst estimates of $8.72 million. Achaogen had a negative net margin of 147.80% and a negative return on equity of 143.44%. Achaogen’s quarterly revenue was up 258.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.48) earnings per share. On average, equities analysts forecast that Achaogen will post ($2.31) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Achaogen, Inc. (AKAO) Cut to Hold at Zacks Investment Research” was originally reported by Daily Political and is the propert of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at http://www.dailypolitical.com/2017/01/13/achaogen-inc-akao-cut-to-hold-at-zacks-investment-research.html.

In other news, major shareholder Equity Opportunities Iv Growth acquired 500,000 shares of the firm’s stock in a transaction that occurred on Monday, December 19th. The stock was purchased at an average cost of $13.50 per share, for a total transaction of $6,750,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 13.80% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in AKAO. Polar Capital LLP increased its position in shares of Achaogen by 45.0% in the third quarter. Polar Capital LLP now owns 145,000 shares of the biopharmaceutical company’s stock worth $695,000 after buying an additional 45,000 shares in the last quarter. Baker BROS. Advisors LP purchased a new position in shares of Achaogen during the third quarter worth approximately $479,000. Sphera Funds Management LTD. purchased a new position in shares of Achaogen during the third quarter worth approximately $6,228,000. Spark Investment Management LLC increased its position in shares of Achaogen by 852.7% in the third quarter. Spark Investment Management LLC now owns 143,865 shares of the biopharmaceutical company’s stock worth $689,000 after buying an additional 128,765 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Achaogen by 52.6% in the third quarter. Northern Trust Corp now owns 23,346 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 8,046 shares in the last quarter. Institutional investors and hedge funds own 42.99% of the company’s stock.

About Achaogen

Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

5 Day Chart for NASDAQ:AKAO

Get a free copy of the Zacks research report on Achaogen (AKAO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.